Tailored-pharmacophore model to enhance virtual screening and drug discovery: a case study on the identification of potential inhibitors against drug-resistant Mycobacterium tuberculosis (3R)-hydroxyacyl-ACP dehydratases.

AIM Virtual screening (VS) is powerful tool in discovering molecular inhibitors that are most likely to bind to drug targets of interest. Herein, we introduce a novel VS approach, so-called 'tailored-pharmacophore', in order to explore inhibitors that overcome drug resistance. Methodology & results: The emergence and spread of drug resistance strains of tuberculosis is one of the most critical issues in healthcare. A tailored-pharmacophore approach was found promising to identify in silico predicted hit with better binding affinities in case of the resistance mutations in MtbHadAB as compared with thiacetazone, a prodrug used in the clinical treatment of tuberculosis. CONCLUSION This approach can potentially be enforced for the discovery and design of drugs against a wide range of resistance targets.

[1]  E. J. North,et al.  Covalent Modification of the Mycobacterium tuberculosis FAS-II Dehydratase by Isoxyl and Thiacetazone , 2014, ACS infectious diseases.

[2]  J. W. Campbell,et al.  Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery. , 2001, Annual review of microbiology.

[3]  G. Besra,et al.  The Mycobacterium tuberculosis FAS‐II condensing enzymes: their role in mycolic acid biosynthesis, acid‐fastness, pathogenesis and in future drug development , 2007, Molecular microbiology.

[4]  J. Bajorath,et al.  Docking and scoring in virtual screening for drug discovery: methods and applications , 2004, Nature Reviews Drug Discovery.

[5]  Hezekiel M. Kumalo,et al.  Per-Residue Energy Footprints-Based Pharmacophore Modeling as an Enhanced In Silico Approach in Drug Discovery: A Case Study on the Identification of Novel β-Secretase1 (BACE1) Inhibitors as Anti-Alzheimer Agents , 2015, Cellular and Molecular Bioengineering.

[6]  H. Matter,et al.  Targeting DnaN for tuberculosis therapy using novel griselimycins , 2015, Science.

[7]  Jeffry D Madura,et al.  Relative free energy of binding and binding mode calculations of HIV‐1 RT inhibitors based on dock‐MM‐PB/GS , 2004, Proteins.

[8]  G. Besra,et al.  Thiacetazone, an Antitubercular Drug that Inhibits Cyclopropanation of Cell Wall Mycolic Acids in Mycobacteria , 2007, PloS one.

[9]  Holger Gohlke,et al.  The Amber biomolecular simulation programs , 2005, J. Comput. Chem..

[10]  M J Harvey,et al.  An Implementation of the Smooth Particle Mesh Ewald Method on GPU Hardware. , 2009, Journal of chemical theory and computation.

[11]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[12]  M. Daffé,et al.  Mycolic acids: structures, biosynthesis, and beyond. , 2014, Chemistry & biology.

[13]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[14]  Guixue Wang,et al.  Comprehensive 3D-QSAR and binding mode of BACE-1 inhibitors using R-group search and molecular docking. , 2013, Journal of molecular graphics & modelling.

[15]  M. Bocchino,et al.  Current Treatment Options for Latent Tuberculosis Infection , 2014, The Journal of Rheumatology. Supplement.

[16]  Ruth Nussinov,et al.  Principles of docking: An overview of search algorithms and a guide to scoring functions , 2002, Proteins.

[17]  Xuemei Li,et al.  Expression, purification and crystallization of the (3R)-hydroxyacyl-ACP dehydratase HadAB complex from Mycobacterium tuberculosis. , 2015, Protein expression and purification.

[18]  Nathalie Reuter,et al.  Measuring and comparing structural fluctuation patterns in large protein datasets , 2012, Bioinform..

[19]  G. Besra,et al.  Pathway to Synthesis and Processing of Mycolic Acids in Mycobacterium tuberculosis , 2005, Clinical Microbiology Reviews.

[20]  Muthusamy Ramesh,et al.  Per-residue energy decomposition pharmacophore model to enhance virtual screening in drug discovery: a study for identification of reverse transcriptase inhibitors as potential anti-HIV agents , 2016, Drug design, development and therapy.

[21]  Mahmoud E. S. Soliman,et al.  Target-Bound Generated Pharmacophore Model to Improve the Pharmacophore-Based Virtual Screening: Identification of G-Protein Coupled Human CCR2 Receptors Inhibitors as Anti-Inflammatory Drugs , 2014 .

[22]  Kurre Purna Nagasree,et al.  AUDocker LE: A GUI for virtual screening with AUTODOCK Vina , 2011, BMC Research Notes.

[23]  Mahmoud E. S. Soliman,et al.  Possible allosteric binding site on Gyrase B, a key target for novel anti-TB drugs: homology modelling and binding site identification using molecular dynamics simulation and binding free energy calculations , 2014, Medicinal Chemistry Research.

[24]  Ryan G. Coleman,et al.  ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..

[25]  M. Soliman.  A Hybrid Structure/Pharmacophore‐Based Virtual Screening Approach to Design Potential Leads: A Computer‐Aided Design of South African HIV‐1 Subtype C Protease Inhibitors , 2013 .

[26]  S. Genheden,et al.  The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities , 2015, Expert opinion on drug discovery.

[27]  S. Lawn,et al.  Tuberculosis control has failed in South Africa--time to reappraise strategy. , 2011, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[28]  A. Saha,et al.  Chemometric design to explore pharmacophore features of BACE inhibitors for controlling Alzheimer's disease. , 2015, Molecular bioSystems.

[29]  Alberto J. M. Martin,et al.  An integrated molecular dynamics, principal component analysis and residue interaction network approach reveals the impact of M184V mutation on HIV reverse transcriptase resistance to lamivudine. , 2014, Molecular bioSystems.

[30]  H. R. Morbidoni,et al.  Mutations in the essential FAS II β‐hydroxyacyl ACP dehydratase complex confer resistance to thiacetazone in Mycobacterium tuberculosis and Mycobacterium kansasii , 2012, Molecular microbiology.

[31]  M. Soliman,et al.  Hybrid Receptor-Bound/MM-GBSA-Per-residue Energy-Based Pharmacophore Modelling: Enhanced Approach for Identification of Selective LTA4H Inhibitors as Potential Anti-inflammatory Drugs , 2016, Cell Biochemistry and Biophysics.

[32]  P. Brennan,et al.  A Common Mechanism of Inhibition of the Mycobacterium tuberculosis Mycolic Acid Biosynthetic Pathway by Isoxyl and Thiacetazone* , 2012, The Journal of Biological Chemistry.

[33]  Yanli Wang,et al.  Computational analysis of the cathepsin B inhibitors activities through LR‐MMPBSA binding affinity calculation based on docked complex , 2009, J. Comput. Chem..

[34]  Yuna Sun,et al.  Molecular basis for the inhibition of β-hydroxyacyl-ACP dehydratase HadAB complex from Mycobacterium tuberculosis by flavonoid inhibitors , 2015, Protein & Cell.

[35]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[36]  D. Zerbib,et al.  The Mycobacterium Tuberculosis FAS-II Dehydratases and Methyltransferases Define the Specificity of the Mycolic Acid Elongation Complexes , 2011, PloS one.

[37]  P. Kaleebu,et al.  Taking forward the World TB Day 2016 theme ‘Unite to End Tuberculosis’ for the WHO Africa Region , 2016, International Journal of Infectious Diseases.

[38]  J. Rademann,et al.  Alzheimer’s Disease: Identification and Development of β‐Secretase (BACE‐1) Binding Fragments and Inhibitors by Dynamic Ligation Screening (DLS) , 2013, ChemMedChem.

[39]  Thierry Langer,et al.  LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters , 2005, J. Chem. Inf. Model..

[40]  M. Soliman,et al.  Sliding Clamp of DNA Polymerase III as a Drug Target for TB Therapy: Comprehensive Conformational and Binding Analysis from Molecular Dynamic Simulations , 2016, Cell Biochemistry and Biophysics.